Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Nephrology Drugs Market Growth From $18.73 Billion In 2026 To $24.31 Billion By 2030 At A CAGR Of 6.7%
The nephrology drugs market has experienced substantial growth in recent years. It is projected to expand from $17.69 billion in 2025 to $18.74 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.9%. This historical expansion is attributable to factors such as the early adoption of antihypertensive agents, an increase in chronic kidney disease cases, the growing hospital infrastructure dedicated to renal care, advancements in dialysis and parenteral treatments, and a rising awareness of kidney-related disorders.
The nephrology drugs market is projected to experience substantial expansion over the upcoming years, with its size forecast to reach $24.32 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. This anticipated growth during the forecast period is fueled by several factors, including the progress in precision medicine for nephrology, the incorporation of AI into renal drug development, the broadening of homecare treatment options, increased investment in biotechnology for kidney-related therapies, and the widespread adoption of digital health monitoring for individuals with kidney conditions. Key developments expected during this period involve tailored kidney care solutions, an increase in kidney disorders linked to hypertension, innovations in renal drug formulations, greater understanding of chronic kidney disease management, and a surge in the use of home-based renal treatments.
Get A Free Sample Report With In-Depth Market Insights:
Nephrology Drugs Market Development Factors: What’s Supporting Demand?
The growing incidence of chronic kidney disease is anticipated to drive the expansion of the nephrology drugs market. Chronic kidney disease (CKD) refers to damaged kidneys that are unable to filter blood effectively. This kidney impairment progresses slowly over an extended period, potentially leading to the accumulation of waste products in the body. Nephrology drugs are primarily utilized in the treatment of chronic kidney disease to enhance kidney function and decelerate the disease’s progression, thereby preventing further bodily harm, which collectively contributes to the growth of the nephrology drug market. For instance, in June 2023, Oxford Academic, Oxford University Press’s academic research platform based in the UK, reported that the prevalence of CKD in the UK is projected to rise by 4% from 8.27 million to 8.61 million people between 2022 and 2032. The expected stage distribution in 2032 is 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Therefore, the increasing prevalence of chronic kidney disease is a key factor driving the growth of the nephrology drug market.
Nephrology Drugs Market Segment Landscape And Growth Outlook
The nephrology drugs market covered in this report is segmented –
1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)
2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa
3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics
4) By ACE Inhibitors: Lisinopril, Enalapril
5) By Antidiabetic Agents: Metformin, Insulin
6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors
Nephrology Drugs Market Transformation Trends: What Innovations Are Driving Change?
Major companies operating in the nephrology drugs market are directing their efforts towards securing approvals for innovative products, such as the U.S. Food and Drug Administration’s clearance of Jardiance (empagliflozin), to better address the needs of their existing clientele. Empagliflozin is a diabetes medication utilized for the control and treatment of type 2 diabetes mellitus. It belongs to the sodium-glucose co-transporter (SGLT-2) group of diabetic drugs. Empagliflozin functions by prompting the kidneys to excrete more glucose in the urine, thereby reducing blood sugar levels. An example of this trend occurred in January 2023, when Eli Lilly and Company, a US-based pharmaceutical firm, and Germany-based Boehringer Ingelheim announced that the Food and Drug Administration had approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets. These tablets are being evaluated as a potential therapy to mitigate the risk of advancing kidney disease and cardiovascular death in adults afflicted with chronic kidney disease (CKD).
Nephrology Drugs Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the nephrology drugs market are AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Otsuka Pharmaceutical Co. Ltd., Mylan N.V.
View The Full Nephrology Drugs Market Report:
Nephrology Drugs Market Regional Analysis And Leading Geography
North America was the largest region in the nephrology drug market in 2025. Europe will be the second-largest growing region in the nephrology drug market in 2025. The regions covered in the nephrology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model